logo
PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan

Download the App Now!

raise
raise
Home
InvestmentsIPOAnlon Healthcare IPO

Anlon Healthcare IPO

Mainboard

Open Date

26 Aug 2025

Close Date

29 Aug 2025

Min Investment

₹ 14,104

Max Investment

₹ 5,00,000

Lot Size

164

Issue Size

₹ 121.03 Cr

Price Range

₹ 86 - ₹ 91
status

This IPO is now Live.

Click here for live price
IPO Timeline
check
IPO Offer Start
26 Aug 2025
check
IPO Offer Ends
29 Aug 2025
check
Allotment Finalisation
1 Sep 2025
check
Refund Initialisation
2 Sep 2025
check
Non-Institutional Buyers (sHNI)
2 Sep 2025
check
Listing of Shares
3 Sep 2025
IPO Subscription Details as on 13 Dec 2025, 02:52 PM
Qualified Instituational Buyers (QiB)
1.07 x
Retail
46.63 x
Non-Institutional Buyer (bHNI)
7.56 x
Non-Institutional Buyer (sHNI)
16.58 x
Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
The company is engaged in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company serves both domestic and multinational corporations. The company has strong promoters and an experienced management team. The company focuses on quality, environment, health and safety (QEHS). The company's operations are dependent upon a limited number of customers. The company has in-house testing, quality control and quality assurance for quality control. The company aims to increase manufacturing capacity to meet growing demand for core products, increase wallet share with existing customers, expand customer base, and improve cost management and operational efficiencies.
rocket

Founded In

2013

rocket

Director

Meet Atulkumar Vachhani

Financials of Anlon Healthcare IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsMar 2023Mar 2024Mar 2025
Operating Revenue11,287.746,658.3712,028.66
Other Income24.2510.8216.85
Total Income
11,312.006,669.1912,045.51
Total Expenses
10,612.685,694.089,356.69
Profit Before Tax699.32975.112,688.82
Total Profit
582.00965.712,051.79

All figures are in lakhs (₹)

border

Utilisation of Proceeds

All figures are in lakhs (₹)

PurposeAmount
The company plans to expand its manufacturing operations by establishing a new manufacturing plant with an installed capacity of 700 MTPA, increasing the total production capacity. The funds will be used for civil and structural work, and equipment, plant and machinery for production, quality control, and utility.3,072
The company intends to repay or prepay certain outstanding secured borrowings (term loans) availed by the company. This will help reduce outstanding indebtedness, maintain a favorable debt-equity ratio, and enable utilization of additional internal accruals for business growth and expansion.500
The company proposes to utilize funds towards meeting its working capital requirements in Financial Years ending March 31, 2026 and March 31, 2027. This is to support the growth of the company and fund its increasing working capital needs.4,315
The company intends to deploy the balance Net Proceeds towards general corporate purposes, including but not limited to strategic initiatives, brand building, strengthening marketing activities, and ongoing general corporate exigencies.-
border
  • Strong product portfolio and scalable business: The company has a wide range of product portfolio of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage, forty-nine (49) products at laboratory testing stage. The company's products span across pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API products. This diverse portfolio enables the company to make its business scalable in both domestic and export markets.
  • Strong Promoters and Experienced Management Team: The company is driven by qualified and dedicated management team led by Promoters who have been associated since inception. The senior management team possesses extensive industry and management experience which has given the company specialized understanding of the complexities involved in manufacturing specific and niche products. This experience and expertise enables the company to understand and anticipate market trends, manage business operations and growth, leverage customer relationships and respond to evolving requirements.
  • High entry and exit barriers due to long customer approval cycles and strict product standards: The company's manufacturing processes and products are subject to stringent specifications and standards. Customer acquisition involves a long approval process including extensive documentary submissions, on-site inspections and audits. This results in high entry barriers for new entrants and exit barriers for existing suppliers. The company's Manufacturing Facility is audited and approved by 33 customers/prospects or their external consultants and regulatory agencies, positioning it well to capitalize on its experience and expertise.
  • In-house Testing, Quality Control and Quality Assurance for quality control: The company has four in-house testing laboratories for adding new generic APIs, process optimisation and testing products against industry standards or customer specifications. The Testing, Quality Control and Quality Assurance team consists of thirty-four (34) members, including twenty-four (24) science graduates and post-graduates. This enables the company to ensure high quality standards, continuous process improvements, and achievement of desired purity levels.
  • Focus on Quality, Environment, Health and Safety (QEHS): The company maintains high quality standards through rigorous quality checks at various stages of manufacturing. It has obtained quality certifications such as ISO 9001:2015, GMP, GMP-WHO, HALAL for its Manufacturing Facility. The facility is a zero liquid discharge facility equipped with an in-house effluent treatment plant and multi-effect evaporator to treat wastewater. The company also prioritizes employee health and safety through various initiatives.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors